APA (7th ed.) Citation

G, B., M, L., JL, B., S, M., K, O., S, P., . . . M, M. (2026). Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: A study from the EBMT Acute Leukemia Working Party. Bone marrow transplantation, 61(4), 462. https://doi.org/10.1038/s41409-026-02805-4

Chicago Style (17th ed.) Citation

G, Bug, et al. "Anti-thymocyte Globulin (ATG)- or Alemtuzumab-based Graft-versus-host Disease Prophylaxis in Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients 40 Years and Older with Acute Lymphoblastic Leukemia in First Complete Remission: A Study from the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation 61, no. 4 (2026): 462. https://doi.org/10.1038/s41409-026-02805-4.

MLA (9th ed.) Citation

G, Bug, et al. "Anti-thymocyte Globulin (ATG)- or Alemtuzumab-based Graft-versus-host Disease Prophylaxis in Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients 40 Years and Older with Acute Lymphoblastic Leukemia in First Complete Remission: A Study from the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation, vol. 61, no. 4, 2026, p. 462, https://doi.org/10.1038/s41409-026-02805-4.